Clinical trials: Lipid Metabolism Disorders
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
Evaluation of Atorvastatin Treatment on Carotid Plaque.
The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the…
- Trial name
- NCT00343655
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia, Familial, Hyperlipidemia
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial…
- Trial name
- NCT00134485
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Severe Hypertriglyceridemia
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
The purpose of this study is to investigate the effects of SC401B (ethyl esters of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] 2 (~1260 mg EPA+DHA), 4 (~2520 mg EPA+DHA) or 6 (~3780 mg EPA+DHA) capsules per day in…
- Trial name
- NCT01997268
- Testing
- SC401B 2 capsules, SC401B 4 capsules, SC401B 6 capsules
- Sponsor
- Sancilio and Company, Inc.
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Dyslipidemia
Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
- Trial name
- NCT01114490
- Testing
- anacetrapib
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386
- Trial name
- NCT04694989
- Testing
- CKD-386, D013, D326, D337
- Where
- South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Niemann-Pick Disease, Type C1
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease
Background: Hydroxypropyl beta cyclodextrin (HPBCD) is being tested for a disease called Niemann-Pick disease type C1 (NPC1). NPC1 is a genetic disorder that results in gradual loss of nervous system function.
- Trial name
- NCT01747135
- Testing
- VTS-270
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Fabry Disease
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding.
- Trial name
- NCT04252066
- Testing
- migalastat
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Amicus Therapeutics
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertriglyceridemia
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics…
- Trial name
- NCT06783881
- Testing
- Kylo-12
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
Chronic Stable Angina
Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions
Exploratory, single-dose, open-label, pharmacokinetic study to establish uptake, plasma levels safety and tolerability of orally administered AUX-001 on an empty stomach (i.e, fasting) as well as after a meal (i.e.
- Trial name
- NCT06249581
- Testing
- AUX-001 40mg once-daily
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Auxilius Pharma sp.z.o.o.
HIV Infections
A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
The purpose of this study is to see if it is safe and effective to give the protease inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems associated with other PIs.
- Trial name
- NCT00002417
- Testing
- Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Gaucher Disease
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease previously treated with Imiglucerase.
- Trial name
- NCT02053896
- Volunteers
- 5 people
- Sponsor
- ISU Abxis Co., Ltd.
Dyslipidemia
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone
The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population
- Trial name
- NCT00171288
- Testing
- fluvastatin, ezetimibe
- Where
- Spain
- Volunteers
- 83 people
- Sponsor
- Novartis
Hypercholesterolemia
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of hypercholesterolemia patients by conducting phase 2a.
- Trial name
- NCT02368613
- Testing
- DW-3102
- Volunteers
- 64 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Generalized Lipodystrophy
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or…
- Trial name
- NCT06502990
- Testing
- Metreleptin
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 1 people
- Sponsor
- Amryt Pharma
Severe Hypercholesterolemia
To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject
To evaluate the effect of concomitant administration of Probucol and Cilostazol (based on Atorvastatin treatment) on the atherosclerosis related markers (including the thickness of the Achilles tendon) in severe…
- Trial name
- NCT02098460
- Testing
- Atorvastatin, Probucol, Cilostazol
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Otsuka Beijing Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.